Diadem Biotherapeutics
Diadem Biotherapeutics is a biotechnology company focused on developing first- and best-in-class therapeutics by engineering extracellular vesicles to modulate immune responses. Their mission is to innovate beyond existing solutions to address unmet medical needs, leveraging expertise in immunology, bioengineering, and drug development. The company’s proprietary DECOSTAR™ platform enables precise costimulatory activation or repression of immune cells, targeting a range of diseases including cancer and autoimmunity.
Industries
Nr. of Employees
small (1-50)
Diadem Biotherapeutics
BioLabs at The Lundquist Institute, 1124 W Carson St., MRL Building, 3rd FL, Torrance, CA 90502
Patents
Products
Engineered extracellular vesicle platform for immune modulation
A platform that programs extracellular vesicles to present signaling molecules on their surface to activate or repress costimulatory and checkpoint receptors for therapeutic applications across autoimmune disease and cancer.
Engineered extracellular vesicle platform for immune modulation
A platform that programs extracellular vesicles to present signaling molecules on their surface to activate or repress costimulatory and checkpoint receptors for therapeutic applications across autoimmune disease and cancer.
Services
Collaborative research and development engagements to design, optimize and advance engineered EV therapeutics that modulate immune receptors.
Collaborative research and development engagements to design, optimize and advance engineered EV therapeutics that modulate immune receptors.
Expertise Areas
- Extracellular vesicle therapeutics
- Bioprocessing and manufacturing scale-up
- Immuno-oncology and immune receptor modulation
- Protein engineering and gene therapy development
Key Technologies
- Engineered extracellular vesicles (EVs)
- Cell line engineering for bioproduction
- Multi-omics (transcriptomics, proteomics, metabolomics)
- Protein engineering
News & Updates
Diadem Biotherapeutics was selected as the winner and recipient of the first Amgen Golden Ticket Award at BioLabs LA.
With lead investment from Novateur Ventures, Diadem Biotherapeutics raised $1.2 million to develop immunotherapies.
Diadem Biotherapeutics completed the Creative Destruction Lab program, a nine-month startup mentorship initiative.
Diadem Biotherapeutics joined IndieBio, a leading biotechnology startup accelerator program.
Diadem Biotherapeutics was selected to pitch at the 2019 QB3 Biotech/Biopharma Pitch Summit.
Received the first Amgen Golden Ticket Award at BioLabs LA.
Diadem Biotherapeutics was selected as the winner and recipient of the first Amgen Golden Ticket Award at BioLabs LA.
With lead investment from Novateur Ventures, Diadem Biotherapeutics raised $1.2 million to develop immunotherapies.
Diadem Biotherapeutics completed the Creative Destruction Lab program, a nine-month startup mentorship initiative.
Diadem Biotherapeutics joined IndieBio, a leading biotechnology startup accelerator program.
Diadem Biotherapeutics was selected to pitch at the 2019 QB3 Biotech/Biopharma Pitch Summit.
Received the first Amgen Golden Ticket Award at BioLabs LA.